Boehringer Ingelheim is preparing for multiple drug launches in the second half of 2025, following strong first-half financial results that saw the company report a 6.3% rise in group net sales to €14 ...

GSK has claimed its second breakthrough designation from the FDA for antibody-drug conjugate GSK5764227, which it licensed from China's Hansoh Pharma in a $1.7 billion deal. The status has been given ...

Moderna has announced a new cost-cutting round as it tries to pare down its annual costs, with a new commitment to cut 10% off its headcount by the end of the year. The target is to reduce its ...

Novartis will cut 427 jobs this year in the US as it prepares for the loss of market exclusivity for its blockbuster heart failure therapy Entresto. The jobs will go in East Hanover, New Jersey – the ...

The San Diego biotech has filed a lawsuit against the Japanese drugmaker and its US subsidiary, NS Pharma, claiming that the ...

J&J has developed two therapies aimed at the estimated two-thirds of MDD patients who continue to experience symptoms despite ...

Daiichi Sankyo has reported its delayed financial results, saying that high spending on third-party manufacturing and a lower-than-expected take-up of its antibody-drug conjugates for cancer led to a ...

Armed with new phase 3 data, Bayer is preparing to file for approval of a new PET imaging agent that could accelerate the ...

Swiss biotech Windward Bio is planning to take on some heavyweight rivals with its TSLP-acting drug for inflammatory respiratory and dermatological diseases – a mission that will be helped by adding ...

Longevity investment went from $3.8bn in 2023 to $8.5bn in 2024 (albeit in the context of a broader biotech market recovery).

Five years after its launch, the FDA’s Project Optimus remained a key theme in discussions at AACR 2026. A dedicated educational session brought together perspectives from regulators, academia, and ...

Specifically, the FDA is delaying its verdict on once-weekly Leqembi Iqlik (lecanemab) as a starting dose for patients ...